All In Biotech

NDA 021308 · Medtech Products

Monistat 1 Combination Pack

Miconazole Nitrate · Topical, Vaginal

Last checked: Nov 19, 2026Latest source record: Jul 22, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jun 29, 2001

Approved uses

2

Original approval plus efficacy supplements

Registered trials

36

8 Phase 3, 0 recruiting

FAERS reports

3,860

847 serious, 89 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 6, 2026.

Uses treats vaginal yeast infections relieves external itching and irritation due to a vaginal yeast infection

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MONISTAT 1 COMBINATION PACK · MICONAZOLE NITRATE 2%,1.2GM · CREAM, INSERT, TOPICAL, VAGINAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Miconazole Nitrate" as an intervention, any sponsor and status, largest first.

All 36 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vulvovaginal burning sensation1,168
  • drug ineffective737
  • vulvovaginal pain685
  • vulvovaginal pruritus388
  • condition aggravated369
  • vulvovaginal discomfort321
  • vaginal haemorrhage290
  • vulvovaginal swelling223
  • pain111
  • hypersensitivity100
  • vaginal discharge94
  • pruritus87

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200520
200622
200713
200837
200966
201046
201146
201275
201318
201427
201535
2016290
2017292
2018336
2019325
2020326
2021373
2022306
2023223
2024296
2025350
2026324

Recalls

1 FDA enforcement reports for this application.

  • Apr 10, 2015 · Class III · Terminated

    Marketed without an approved NDA/ANDA: The distributed units of Monistat 1 Simple Cure include only the 1200 mg vaginal suppository; the approved NDA requires both a 1200 mg vaginal suppository and the 2% topical cream.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 71 on PubMed

Sponsor: Medtech Products

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.